BTK and systemic lupus erythematosus: BTK inhibition by ibrutinib significantly decreased B cell and APC activation and reduced the populations of cDCs, macrophages, neutrophils, and MCs, resulting in dampened humoral and cellular autoimmunity in lupus-prone mice [106].